Shayna Korol,  —

Researchers are investigating whether treatments for other disorders might benefit people with a newly identified type of Charcot-Marie-Tooth disease (CMT) that may be a common recessive form of hereditary neuropathy. They are inviting people diagnosed with CMT but with no clear disease-causing mutation to help by joining a registry…

Charcot-Marie-Tooth disease (CMT) does not significantly affect the outcomes of pregnancies but a pregnancy can cause CMT symptoms to worsen, according to a study in Italy, which also recommends that expectant mothers with CMT be carefully monitored. While outcomes such as miscarriage and newborn health were similar between women…

A group of researchers is inviting adult Charcot-Marie-Tooth disease (CMT) patients who have mobility or dexterity limitations and/or their caregivers to take an online survey regarding their experiences using medicines. The experiences that people living with CMT have had with medications may help researchers better understand treatment safety…

People with Charcot-Marie-Tooth (CMT) and mutations in the MPZ gene have highly variable disease symptoms, according to a recent Japanese study, which found that these patients may be diagnosed with either demyelinating or axonal forms of the disorder. Notably, the MPZ genetic variations seen in Japanese patients are…

AcuraStem has identified 37 compounds that improve nerve cell survival and might help treat Charcot-Marie-Tooth disease type 2A (CMT2A), according to a press release from the CMT Research Foundation. CMT2 accounts for roughly one-third of CMT cases and CMT2A is its most common subtype. Inherited mutations in…

An international observational study using a smartphone-based app called CMT&Me is exploring the impact of Charcot-Marie-Tooth disease (CMT) on patients and caregivers. The study (NCT03782883) was designed by Vitaccess in collaboration with Pharnext. Its goal is to collect detailed patient-reported data to help researchers and clinicians…

Pharnext and the Charcot-Marie-Tooth Association (CMTA) have partnered to find new biomarkers associated with Charcot-Marie-Tooth disease type 1A (CMT1A), the most common subtype of the disease, according to a press release. Its goal is to identify and validate CMT1A biomarkers that signal responses to treatment, and…

Raremark, an online rare disease patient community, has launched a digital platform called Xperiome, aimed at streamlining the search for new medicines for rare disorders and incorporating more patient input into research. The goal is to help the pharmaceutical industry deliver innovative new therapies faster and smarter, the…

The extra copy of the PMP22 gene that causes Charcot-Marie-Tooth disease type 1A (CMT1A) leads to a potentially toxic buildup of the PMP22 protein inside cells because the excess protein cannot be folded properly and is not transported to its rightful place in the cell membrane, according…

CMT Australia, a charity association aiming to raise awareness and empower people with Charcot-Marie-Tooth disease (CMT) to live their lives to the fullest, has received $10,000 to support the organization’s CMT Aussie Kids youth program. The Commonwealth Bank Community Grant will support activities for younger CMT patients, as…